Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 421

The DOI matches its Crossref record; 365 of the 365 references it cites were found in a registry or an index.

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder

Open access
Grunze, Heinz, Vieta, Eduard, Goodwin, Guy M., Bowden, Charles, Licht, Rasmus W., Möller, Hans-Jürgen, Kasper, Siegfried, on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders·2013·The World Journal of Biological Psychiatry

Abstract

OBJECTIVES: These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults. METHODS: Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned. RESULTS: Maintenance trial designs are complex and changed fundamentally over time; thus, it is not possible to give an overall recommendation for long-term treatment. Different scenarios have to be examined separately: Prevention of mania, depression, or an episode of any polarity, both in acute responders and in patients treated de novo. Treatment might differ in Bipolar II patients or Rapid cyclers, as well as in special subpopulations. We identified several medications preventive against new manic episodes, whereas the current state of research into the prevention of new depressive episodes is less satisfactory. Lithium continues to be the substance with the broadest base of evidence across treatment scenarios. CONCLUSIONS: Although major advances have been made since the first edition of this guideline in 2004, there are still areas of uncertainty, especially the prevention of depressive episodes and optimal long-term treatment of Bipolar II patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/15622975.2013.770551

Cites

365 of 365 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 365 references

Research works printed but not linked: 52

  1. Abou-Auda HS, 2008, Bipolar Disord, 10, 369, 10.1111/j.1399-5618.2007.00549.x · doi:10.1111/j.1399-5618.2007.00549.x
  2. Agarkar S, 2011, J Neuropsychiatry Clin Neurosci, 23, 12, 10.1176/jnp.23.2.jnpe12 · doi:10.1176/jnp.23.2.jnpe12
  3. Anderson J, 2000, J Rheumatol, 27, 540
  4. Angst J, 1981, Handbook of Biological Psychiatry, 225
  5. Angst J, 1995, Schweiz Arch Neurol Psychiatr, 146, 17
  6. Becker D, 2002, Eur Psychiatry, 17, 349, 10.1016/S0924-9338(02)00688-0 · doi:10.1016/s0924-9338(02)00688-0
  7. Benabarre A, 2009, Actas Esp Psiquiatr, 37, 143
  8. Bowden CL, 1997, Psychopharmacol Bull, 33, 693
  9. Bowden CL, 2012, Acta Psychiatry, 64, 1013
  10. Calabrese J, 2003, J Clin
  11. Carta MG, 2006, Clin Pract Epidemiol Ment Health, 2, 19, 10.1186/1745-0179-2-19 · doi:10.1186/1745-0179-2-19
  12. Dunner DL, 1998, J Clin Psychiatry, 59, 48
  13. Emrich HM, 1992, Prog Neuropsychopharmacol Biol Psychiatry, 16, 691, 10.1016/0278-5846(92)90025-A · doi:10.1016/0278-5846(92)90025-a
  14. Ernst CL, 2002, J Clin Psychiatry, 63, 42
  15. Fitzgerald BJ, 2002, Pharmacotherapy, 22, 1500, 10.1592/phco.22.16.1500.33697 · doi:10.1592/phco.22.16.1500.33697
  16. Garcia-Lopez A, 2001, Actas Esp Psiquiatr, 29, 327
  17. Ghaemi SN, 2004, Ann Clin Psychiatry, 16, 69, 10.1080/10401230490453103 · doi:10.1080/10401230490453103
  18. 10.4088/JCP.08m04301 · DOI
  19. Goncalves N, 1985, Nervenarzt, 56, 43
  20. Goodwin FK, 2002, J Clin Psychiatry, 63, 5
  21. Grande I, 2012, Int J Neuropsychopharmacol, 1
  22. Greil W, 1999, Int Clin Psychopharmacol, 14, 283, 10.1097/00004850-199914050-00003 · DOI
  23. Greil W, 1999, Int Clin Psychopharmacol, 14, 277, 10.1097/00004850-199914050-00002 · DOI
  24. Grunze H, 2004, Valproat bei manisch-depressiven (bipolaren) Erkrankungen
  25. Harvey PD, 2006, J Clin Psychiatry, 67, 14
  26. Hayes SG, 1989, J Clin Psychiatry, 50, 35
  27. Hullin RP, 1972, Lancet i, 1044
  28. Kessing LV, 2011, J Psychopharmacol
  29. Lancon C, 1996, Encephale, 22, 468
  30. Lebowitz BK, 2001, Neuropsychiatry Neuropsychol Behav Neurol, 14, 177
  31. Moskowitz AS, 1991, J Clin Psychopharmacol, 11, 272, 10.1097/00004714-199108000-00020 · doi:10.1097/00004714-199108000-00020
  32. Murru A, 2011, Eur Psychiatry
  33. Nolen WA, 2008, Richtlijn bipolaire stoornissen
  34. Placidi GF, 1986, J Clin Psychiatry, 47, 490
  35. Popovic D, 2011, Eur Neuropsychopharmacol
  36. Puri BK, 1995, Br J Clin Pract, 49, 333, 10.1111/j.1742-1241.1995.tb10004.x · doi:10.1111/j.1742-1241.1995.tb10004.x
  37. Puzynski S, 1984, Psychopharmacol Bull, 20, 151
  38. Quitkin FM, 1981, Psychopharmacol Bull, 17, 142
  39. Riedel M, 2010, Expert Opin Drug Saf, 9, 659, 10.1517/14740338.2010.486787 · doi:10.1517/14740338.2010.486787
  40. Sachdev PS, 1986, Am J Psychiatry, 143, 942, 10.1176/ajp.143.7.942 · doi:10.1176/ajp.143.7.942
  41. Sachs GS, 2000, Postgrad Med Spec Report, 1
  42. Sartorius N, 2007, Int J Neuropsychopharmacol, 10, 1
  43. Singh V, 2012, Bipolar Disord, 14, 13
  44. Szabo CP, 1993, S Afr Med J, 83, 442
  45. Vieta E, 2011, New Engl J Med, 364, 1581
  46. 10.1016/j.jad.2009.02.028 · DOI
  47. Viguera AC, 2007, J Clin Psychiatry, 68, 29
  48. World Health Organization, 1992, Clinical descriptions and diagnostic guidelines
  49. Yoshimura R, 2006, Pharmacopsychiatry, 39, 233, 10.1055/s-2006-951386 · doi:10.1055/s-2006-951386
  50. Young AH, 2012, World J Biol Psychiatry
  51. Zarate CA, 1995, J Clin Psychiatry, 56, 108
  52. Zis AP, 1980, Psychopharmacol Bull, 16, 47

Cited by

See all 421

Metadata

Authors
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Venue
The World Journal of Biological Psychiatry
Published
2013-03-13
Volume
14
Issue
3
Pages
154-219
ISSN
  • 1562-2975 (ISSN-L)
  • 1814-1412
OpenAlex
W2170882187
Cited by
421
References
365
FWCI
31.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. https://app.cochat.ai/papers/10.3109/15622975.2013.770551
The paper
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. (2013). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622975.2013.770551

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.